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The purpose of this study was to examine prophylactic eﬃcacy of probiotics in neonatal sepsis and meningitis caused by E. coli K1.
The potential inhibitory eﬀect of Lactobacillus rhamnosus GG (LGG) on meningitic E. coli K1 infection was examined by using (i)
in vitro inhibition assays with E44 (a CSF isolate from a newborn baby with E. coli meningitis), and (ii) the neonatal rat model
of E. coli sepsis and meningitis. The in vitro studies demonstrated that LGG blocked E44 adhesion, invasion, and transcytosis in
a dose-dependent manner. A signiﬁcant reduction in the levels of pathogen colonization, E. coli bacteremia, and meningitis was
observedintheLGG-treatedneonatalrats,asassessedbyviablecultures,comparedtothelevelsinthecontrolgroup.Inconclusion,
probiotic LGG strongly suppresses meningitic E. coli pathogens in vitro and in vivo. The results support the use of probiotic strains
such as LGG for prophylaxis of neonatal sepsis and meningitis.
Copyright © 2009 Sheng-He Huang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Bacterial sepsis and meningitis continue to be the most
common serious infection in neonates [1–3]. Group B
Streptococcus (GBS) and E. coli are the two most common
bacterial pathogens causing neonatal sepsis and meningitis
(NSM) [2, 3]. Invasive GBS disease emerged in the 1970s
as a leading cause of newborn morbidity and mortality in
the US [4]. Extensive studies demonstrated that intrapartum
prophylaxis (IP) of GBS carriers and selective administration
of antibiotics to neonates decrease newborn GBS infection
by as much as 80 to 95% [4–7] .H o w e v e r ,am a j o rc o n c e r n
is whether the IP use of antibiotics aﬀects the incidence and
the resistance of early onsetneonatal infection with non-GBS
pathogens [4–7]. Currently, the focus has been shifted to E.
coli, which is a leading cause of infection among neonates,
particularly among those of very low birth weight (VLBW)
[8]. Although initially most multicenter reports showed
stableratesofnon-GBSearlyonsetinfectionwithIPforGBS,
more recent studies challenge this conclusion, suggesting an
increasing incidence of early onset E. coli infections in low
birth weight and VLBW neonates and a rising frequency
of ampicillin-resistant E. coli infections in preterm infants
[9, 10]. Widespread antibiotic use (WAU), particularly with
broad-spectrum antimicrobial agents, may result in a rising
incidence of neonatal infections with antibiotic resistance,
which is an ecological phenomenon stemming from the
response of bacteria to antibiotics [11]. Antibiotic resistance
has emerged as a major public health problem during the
past decade [12]. WAU will certainly worsen the ongoing
antimicrobial resistance crisis.
The development of microbial infections is determined
by the nature of host-microbe relationships. As most
microbes form a healthy symbiotic “superorganism” with2 International Journal of Microbiology
the hosts, a holistic balance of this relationship is essential
to our health [13]. This ecological balance is aﬀected by
environmental factors, which include the use of antibi-
otics, immunosuppressive therapy, irradiation, hygiene, and
imbalance of nutrition. Some of the mentioned factors
may contribute to a decline in the incidence of microbial
stimulationthatmaydampenhostdefenseandpredisposeus
to infectious diseases [14, 15]. Therefore, the introduction of
beneﬁcial microorganisms such as probiotics into our body
is a very attractive rationale for modulating the microbiota,
improving the symbiotic homeostasis of the superorganism,
and providing a microbial stimulus to the host immune
system against pathogens including meningitic E. coli K1.
As probiotics help to maintain ecological balance, the use
of probiotics for the prophylaxis of early onset neonatal
meningitic infections may overcome the major disadvantage
of WAU, which disturbs the normal microbiota. Studies
using LGG have demonstrated that atopic dermatitis of
newborns can be prevented in 50% of cases if mothers
take probiotics and neonates ingest LGG during the ﬁrst
6 months of life [16]. Newborns fed with LGG-enriched
formula grew better than those fed with the regular one [17].
LGG has been shown to decrease the frequency and duration
of diarrhea caused by E. coli and other pathogens [18, 19].
However, it is unknown whether probiotics are eﬀective in
preventing NSM. In order to dissect this issue and develop
probiotics as a better approach for the prophylaxis of NSM
caused by meningitic pathogens including GBS and E. coli
K1, prophylactic eﬃcacy of LGG in NSM was tested in vitro
and in vivo.
2.MaterialsandMethods
2.1. Bacterial Strains and Culture Conditions. The commer-
cial probiotic strain used was L. rhamnosus GG (LGG)
(ATCC 53103). The bacterial pathogen used was E. coli
E44, a rifampin-resistant strain of a clinic isolate E. coli
RS218 (O18:K1:H7) from the cerebrospinal ﬂuid (CSF) of
a newborn infant with meningitis [20]. LGG was grown
in Rogosa SL broth (Difco) at 37◦C for 18 hours. The
culture was centrifuged (10000×g f o r5m i n u t e sa t4 ◦C),
and bacteria were suspended in cell culture medium. The
ﬁnal suspension was adjusted to obtain the appropriate
concentration. E44 was grown at 37◦C in Luria-Bertani
(LB) or brain-heart infusion (BHI) broth with rifampin
(100μg/mL) overnight. After centrifugation, bacteria were
suspended in cell culture medium. The number of CFU was
determined by plating serial 10-fold dilutions from bacterial
suspensions on LB (for E44) or Rogosa SL (for LGG) agar
plates. Plates were incubated at 37◦Ci naC O 2 atmosphere
overnight.
2.2. Cell Culture Model of Intestinal Epithelial Cell Line.
C a c o - 2c e l l sw e r eo b t a i n e df r o mA m e r i c a nT y p eC u l t u r e
Collection (ATCC, Rockville, Md, USA) and used between
passages 19 and 23 as older passages have shown to be less
permissivetobacterialentry[21].Caco-2cellsweregrownin
Eagle’sMinimumEssentialMediumsupplementedwith20%
heat-inactivated FCS, 1% Cellgro nonessential amino acids,
2mM L-glutamine, 1mM sodium pyruvate, 100000U/L
penicillin, 100mg/L streptomycin, and 2.5mg/L Fungizone.
The cells were incubated in a 5% CO2 atmosphere at 37◦C
in T-75 tissue culture ﬂasks coated with rat-tail collagen.
Cells used for the quantitative adhesion and invasion assays
were seeded at 105 cells per well, in a 24-well tissue
culture plate coated with rat-tail collagen, and assays were
performed at a minimum of 12 days postconﬂuence. At this
time, the polarized monolayers exhibited dome formation,
characteristic of transporting epithelia, and evidence of end-
stage diﬀerentiation [22].
2.3. Adhesion and Invasion Assays. Bacterial inocula were
prepared in experimental media without antibiotics (Ham’s
F12: Medium 199 1X Earl’s Salts in a 1:1 ratio, 5%
heat-inactivated fetal bovine serum, 1% sodium pyruvate,
and 0.5% L-glutamine). Caco-2 cells were inoculated with
1×107 bacteria per well, to give a multiplicity of infection
of 100 and be incubated for 90 minutes at 37◦Ci n5 %C O 2
atmosphere to allow bacterial adhesion and entry. The adhe-
sion assays were carried out as described previously [23].
To determine the total number of cell-associated bacteria,
the cells were washed three times with medium and lysed
with 100μl of 0.5% Triton X-100 for eight minutes followed
immediately by the addition of 50μl of sterile water. The
monolayers remained intact throughout the incubation and
washing phases of the assay until lysis. This concentration
of Triton X-100 did not aﬀect bacterial viability for at least
30 minutes (data not shown). Samples were diluted and
plated onto sheep blood agar plates to determine the number
of colony forming units (CFUs) recovered from the lysed
cells. The number of associated bacteria was determined
after washing oﬀ the unbound bacteria. A percent adhesion
was calculated by [100×(number of intracellular bacteria
recovered)/(number of bacteria inoculated)]. Each experi-
ment was carried out in triplicate, and results presented are
representative of the repeated assays.
For invasion assays, the same number (107)o fb a c t e r i a
was added to conﬂuent monolayers of Caco-2 with a
multiplicity of infection of 100 [24]. The monolayers were
incubated for 1.5 hours at 37◦Ct oa l l o wi n v a s i o nt oo c c u r .
The number of intracellular bacteria was determined after
the extracellular bacteria were eliminated by incubation of
the monolayers with the experimental medium containing
gentamicin (100μg / m L )f o r1h o u ra t3 7 ◦C. Results were
expressedeitheraspercentinvasion[100×(numberofintra-
cellularbacteriarecovered)/(numberofbacteriainoculated)]
or relative invasion (percent invasion as compared to the
invasion of the parent E. coli K1 strain).
2.4. Transcytosis Assay. Caco-2 cells were cultured on 6.5-
mm diameter, collagen-coated Transwell polycarbonate cell
culture inserts with a pore size of 3μm (Corning Costar
Corp., Cambridge, Mass, USA) for at least 5 days as
previously described [25, 26]. This in vitro model of the
gut barrier allows separate access to the upper chamber
(gut side) and lower chamber (blood side) and permitsInternational Journal of Microbiology 3
mimicking of NSM E. coli penetration across the gut barrier
into the blood stream. Human epithelial cells are polarized
and exhibit a transepithelial electric resistance (TEER) of at
least 300Ω/cm2 [27] as measured with an Endohm volt/ohm
meter in conjunction with an Endohm chamber (World
Precision Instruments, Fla, USA) as previously described
[26]. On the morning of the assay, the Caco-2 monolayers
were washed, experimental medium was added, 105 E44
cells were added to the upper chamber (total volume,
200μL), and the monolayers were incubated at 37◦C. At 2,
4, and 6 hours, samples of 30μL were taken from the lower
chamber (an equivalent volume of medium was immediately
added, maintaining a total bottom volume of 1mL) and
plated for CFU determination. The integrity of the Caco-2
monolayer was assessed by measuring TEER and horseradish
peroxidase (HRP) permeability. The results were expressed
as the percentage of initial inoculum transcytosed. The cell
numbers were determined based on the viable-cell counts on
the blood agar plates.
2.5.CompetitiveExclusionAssays. Threediﬀerentprocedures
(adhesion, invasion, and transcytosis) were used to assess
exclusion of E44 strain by LGG. Exclusion was assessed
by performing preinfection experiments in which cultured
intestinal epithelial cells were ﬁrst incubated with LGG.
NSM strain E44 was added for further incubation. The
numbers of strains adhering to, invading, or crossing the
intestinal cells were determined as described above. For each
assay, a minimum of three experiments was performed with
successive passage of intestinal cells. To test the eﬀects of
LGG on E. coli K1 adhesion to and invasion of Caco-2, the
cells were subcultured into 24-well tissue culture plates and
then preincubated at 37◦Cw i t h1×107 and 1×108 CFU of
LGGinthecompleteexperimentalmediumfor3hours.After
incubation with LGG, 1×107 CFU of E44 was added to the
cultures followed by incubation at 37◦C for 2 hours to allow
adhesion and invasion to occur. Adhesion/invasion assays
andresultexpressionswereperformedasdescribedabove.To
examine eﬀects of LGG on E44 translocation across human
intestinal epithelial cell monolayers, the cell cultures were
incubated at 37◦Cw i t h1×107 to 1×108 CFU of LGG for
3 hours. After incubation with LGG, 1×107 CFU of E44 was
added to the upper chamber of Transwell. The appearance
of E44 in the bottom chamber was determined as described
above.
2.6. Neonatal Rat Model of Hematogenous E. coli K1 Meningi-
tis. The ability of E. coli strains E44 to colonize and cause
NSM in vivo was examined in a neonatal rat model. All
animal experiments were carried out with prior approval
from the Animal Care Committee of Childrens Hospital
Los Angeles Research Institute (Calif, USA). Pathogen-free
Sprague Dawley rats with timed conception delivered pups
on the seventh day after arrival. In order to determine the
therapeutic eﬃcacy of LGG, a pilot study with two groups
(14 pups/group) of animals was carried out. The pups were
pooled and randomly distributed into the experiment group
(LGG) and control group (PBS). Pups on day 2 of life
received oral LGG or PBS by feeding the pups using an FB
Multiﬂex tip (from Fisher Scientiﬁc, Pa, USA). Daily dose of
LGG was 1010 CFU/kg or 107 CFU/g. Control rats received
PBS only. At 5 days of age, all pups received 109 CFU/pup of
E44 by feeding the animals with the same delivery approach.
Stool, blood, and CSF samples were taken for quantitative
cultures at 48 hours after oral inoculation. Stool samples
were obtained by aspirating rectal contents through 1cm of
sterile plastic tubing (intramedic polyethylene tubing, outer
diameter 0.61mm) with a sterile tuberculin syringe. The
stool aspirate and tubing were placed in 950μLo fB H I
brothandhomogenized.Thissolutionwasplatedontosheep
blood agar or grown in BHI broth. Intestinal colonization
was deﬁned as a positive stool culture, from either the agar
plate or the overnight broth. Blood cultures were obtained
in a sterile fashion from the right external jugular vein.
Blood was diluted in BHI and plated onto sheep blood agar.
Bacteremia was deﬁned as a positive blood culture. CSF
samples were obtained and cultured as described previously
[28]. Meningitis was deﬁned as positive CSF cultures.
2.7. Statistical Analysis. Data were analyzed as described
previously [29]. Analysis of variance (ANOVA) and covari-
ates followed by a multiple comparison test such as the
Newmann-Keuls test were used to determine the statistical
signiﬁcance between the control and treatment groups; P<
.05 was considered to be signiﬁcant.
3. Results
3.1. Eﬀects of Probiotics on Meningitic E. coli K1 (E44)
Adhesion to and Invasion of Human Intestinal Epithelial
Cells in vitro. Caco-2 is used as an in vitro model for
testing eﬀects of LGG on meningitic E. coli adhesion to
and invasion of the gut barrier since it has been one
of the most relevant in vitro models for the studies of
small intestinal epithelial cell diﬀerentiation and transport
properties [22]. The ability of LGG to interfere with the
adhesion of E. coli K1 to Caco-2 cells was examined by
competitive exclusion/adhesion inhibition assays. In this
study, Caco-2 cells were preincubated with diﬀerent doses of
LGG (106 to 108 CFU) before the addition of meningitic E.
coli K1 strain E44. As shown in Figure 1(a), LGG was able to
competitively inhibit E44 invasion of Caco-2 cells in a dose-
dependent manner (P<. 01). Eﬀects of LGG on the invasive
phenotype of strain E44 into Caco-2 cells were determined
utilizing competitive exclusion/invasion inhibition assays.
Caco-2 cells were preincubated with diﬀerent doses of LGG
(107 to 108 CFU) before addition of meningitic E. coli K1
strain E44. The intracellular E. coli K1 pathogens were
determined by the gentamicin protection assay, which is
based upon the principle that intracellular organisms are
“protected” from the bactericidal eﬀects of gentamicin, while
extracellular organisms are killed. The invasion rate of E44
at the zero concentration of LGG was assigned as 100% and
the eﬀects of probiotic preincubation were compared to this
control level (Figure 1(b)). As shown in Figure 1(b), LGG
blocked E44 invasion of Caco-2 cells in a dose-dependent4 International Journal of Microbiology




























































Figure 1:Eﬀects ofLGGon E.coliK1adhesion toandinvasion of Caco-2.Epithelialcells were incubated withvariousdoses of L.rhamnosus
for 3 hours before adding bacteria. Adhesion and invasion assays were carried out as described above. All values represent the means of
triplicate determinations. The results were expressed as adhesion (Figure 1(a)) or invasion activities (Figure 1(b)) compared to that of the
control without LGG. Error bars indicate standard deviations. ∗P<. 05; ∗∗P<. 01.
manner. The invasion ability of E44 was reduced by 78% at
1×108 CFU of LGG (P<. 01). A similar result was obtained
with rat intestinal epithelial cell line IEC6 (data not shown).
3.2. Probiotics-Induced Blockage of Meningitic E. coli K1
Transcytosis Across the Intestinal Epithelial Barrier in vitro.
The in vitro double chamber culture system in which cells
are grown on porous ﬁlters has proven to be a valuable
tool for the evaluation of bacterial transcytosis across the
endothelial or epithelial barrier [25–27]. In order to examine
whether LGG inﬂuences the internalized bacteria across the
monolayers of Caco-2 cells using thetranscellular pathway
with or without the enhancement of the epithelial bar-
rier functions, competitive exclusion/transcytosis inhibition
assays were carried out. In this experiment, Caco-2 cells were
preincubated with diﬀerent doses of LGG (107 to 108 CFU)
before the addition of meningitic E. coli K1 strain E44. After
incubation with LGG, 1×107 CFU of E44 was added to the
upper chamber of Transwell. The appearance of E44 in the
bottom chamber was determined. Our studies suggested that
LGG was able to signiﬁcantly reduce transcytosis of E44
across the Caco-2 monolayers at 1×108 CFU of LGG at 4
hours (P<. 05) (Figure 2(a)). To further determine whether
LGG inﬂuenced the barrier function that led to decreased
E44 crossing the Caco-2 monolayers from the apical to the
basolateral side the eﬀect of LGG on the Caco-2 barrier
function was evaluated by measuring the passage of HRP
throughconﬂuentmonolayers.HRPassaywascarriedoutas
previously described [30]. The HRP concentrationwas deter-
mined spectrophotometrically at 470nm to determinethe
peroxidase activity. E44 CFUs in the lower chamber were
signiﬁcantly reduced in the experiment group (E44 + LGG)
at1×108 CFUofLGGcomparedtothecontrol(E44without
adding LGG) (P<. 05) (Figure 2(a)). However, stable TEER
(Figure 2(b)) and HRP activity (25.6±1.7μg/mL at 6 hours)
were observed in both groups, suggesting that the barrier
function or permeability was not remarkably altered.
3.3. Eﬀects of LGG on Colonization, Bacteremia, and Meningi-
tis of E. coli K1 in Neonatal Rats. The in vitro experiments
demonstrated that the probiotic agent LGG was able to
signiﬁcantly block meningitic E. coli K1 adhesion, invasion,
and transcytosis. Next, the probiotics-induced blocking
eﬀects on meningitic pathogens were further examined in
the neonatal rat model of E. coli K1 meningitis. LGG was
administrated orally to 2-day-old rats for 3 days before E. coli
K1 infection. The 5-day-old rats were infected with E. coli
E44, and the stool, blood, and CSF samples were cultured
for indication of intestinal colonization, bacteremia, and
meningitis, respectively. Our study showed that the rates of
E44 intestinal colonization, bacteremia, and meningitis were
signiﬁcantly diﬀerent between the experiment group with
LGG and the control receiving PBS (Table 1). Quantitative
cultures of LGG were also done with the blood samples
from the pups receiving LGG. No LGG was detected. The
average number of intestinal E. coli K1 colonies in the
animals given LGG was signiﬁcantly lower than that of the
control group, suggesting that LGG is able to suppress E.
coli K1 colonization in the rat intestine. No bacteremia and
meningitis occurred in the whole animal group inoculated
with LGG. In contrast, among the animals in the control
group, 100% of animals colonized with meningitic E. coli
K1 and the majority (64%) of the rats had bacteremia (from
>105 to 108 CFU/mL), which is critical for the development
of meningitis. Twenty one percent of the rats in the control




































6 4 2 0






























Figure 2: Eﬀects of LGG on E. coli K1 translocation across Caco-2 monolayers (a) and transepithelial electrical resistance (TEER) of Caco-2
monolayers(b).(a)Epithelialcells wereincubatedwithvariousdosesof L.rhamnosus for3hours beforeadding 107 E44. Transcytosisassays
were carried out as described above. All values represent the means of triplicate determinations at 4 hours. Experiments were repeated three
times. Error bars indicate standard deviations. ∗P<. 05. (b) TEER was not signiﬁcantly altered after 0 to 6 hours incubation.
Table 1: The rates of E. coli colonization, bacteremia, and meningitis in rat pups after receiving E44 or E44 plus LGG.
Treatment No. of animal No. of pups with positive
LGG culture in blood
No. (%) of pups with
intestinal colonization
(E44)
No. (%) of pups with
bacteremia (105 to
108 CFU/mL) (E44)
No. (%) of pups with
meningitisa
E44 14 — 14 (100) 9 (64) 3 (21)
E44 + LGG 14 0 8 (57) 0 (0) 0 (0)
a Deﬁned as positive culture of CSF.
4. Discussion
In recent years, probiotic microorganisms have received
increasing attention both from academics and from practi-
tioners because of clinical observations suggesting that they
are useful in preventing or treating some infectious diseases
and allergic disorders [13–18, 31, 32]. These diseases include
diarrhea, vaginitis, inﬂammatory bowel disease, and atopic
dermatitis. Both prophylactic and therapeutic eﬀects have
been observed in both children and adults [32]. In the
current studies, we have demonstrated for the ﬁrst time
that probiotics are able to suppress meningitic E. coli K1
penetration across intestinal epithelial cells in vitro and
reduce bacteremia/meningitis in neonatal rats.
Bacterial adhesion and invasion are two subsequent steps
essential for pathogen entry into the host cells. Enteric
pathogens such as E. coli K 1m u s tp e n e t r a t ea c r o s st w o
tissue barriers, the gut and the blood-brain barrier (BBB),
in order to cause meningitis [1, 2]. E. coli K1 binding to
and invasion of intestinal epithelial cells are a prerequisite
for bacterial crossing of the gut barrier in vivo [33, 34].
In order to understand how probiotics suppress meningitic
E. coli translocation through gastrointestinal epithelium, the
present studies examined the eﬀects of LGG on E. coli K1
strain E44 adhesion, invasion, and transcytosis in the human
colon carcinoma cell line Caco-2, which is one of the most
relevant in vitro models of gut epithelium for the studies
of small intestinal epithelial cell diﬀerentiation, transport
properties, and barrier functions [21–23, 33, 34]. The cells
are fully diﬀerentiated after 14 days in culture, at which
time they form a polarized monolayer with tight junctions
and demonstrate dome formation, typical of transporting
epithelial monolayers [21–23]. This in vitro cell culture
model has been successfully used for identiﬁcation of E.
coli K1 S ﬁmbria and ibeA as virulence factors required for
eﬃcient intestinal epithelial adhesion and invasion [23, 33].
Thebarrierintegrityofthediﬀerentiated Caco-2 monolayers
was assessed by TEER and HRP permeability. Stable TEER
values and HRP activities were observed in both the control
andtreatmentgroups,suggestingthatthebarrierfunctionor
permeability was not remarkably altered. Our results show
that in the in vitro Caco-2 cell line experiments LGG reduces
E. coli K1 adhesion, invasion, and transcytosis.
To further assess the role of LGG inthe suppression of
meningitic E. coli K1 infection, we conducted the animal
study to test its biological functions using the newborn
rat model of experimental hematogenous meningitis. This
animal model of E. coli bacteremia and meningitis has
been successfully established and used by us to assess the
ability of pathogens to cross the gut barrier and the BBB6 International Journal of Microbiology
in vivo [1, 2, 33]. Experimental E. coli bacteremia and
meningitis in newborn murines have important similarities
to human newborn E. coli infection, for example, age-
dependency, hematogenous infection of meninges, without
need for adjuvant or direct inoculation of bacteria into CSF
[1, 2, 28]. The availability of this animal model enables
us to examine the clinical relevance of probiotics-induced
protective eﬀects on newborns against the development of
NSM. We showed that LGG was able to signiﬁcantly reduce
the pathogen intestinal colonization and the genesis of E. coli
K1bacteremia.LGGwasnotdetectedinthebloodsamplesof
the animals treated with the probiotics, suggesting that LGG,
which has the most extensive safety assessment record and
has never been the suspected causal agent of sepsis [35, 36],
exhibitedahighdegreeofsafetyintheneonatalmurinepups.
Twenty one percent of the animals in the control group had
meningitis. No meningitis occurred in the rat pups treated
with LGG. It has been previously shown that a high degree of
bacteremia (>105 bacteria/mL) is a primary determinant for
meningeal invasion by E. coli K1 [2] .T h er a t eo fb a c t e r e m i a
in the animals treated with LGG (64%) was signiﬁcantly
lower than that of the control group (100%), indicating that
the signiﬁcantly decreased or even abolished translocation of
the pathogen across the gut barrier led to a reduced number
of bacteria or no bacteria entry into the bloodstream. This
eventuallyresultedinnopathogenscrossingtheBBBtocause
meningitis.
In conclusion, the results obtained in the current
studies suggest that preventive administration of probiotic
lactobacilli to infants may lead to enhanced resistance to
neonatal bacterial sepsis and meningitis due to suppression
of pathogen translocation across the gut barrier. Probiotics
could be useful to correct ecological disorders in human
intestinal microbiota associated with NSM and might play a
protective role in excluding pathogens from the intestine and
preventing infections.
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